ideasIdea
Plan the second CAR-T target before the first one is lost
Cell therapies fail when the tumour stops showing the marker they were built to find. Preparing an alternative product in advance would let doctors switch quickly.
Antigen-negative relapse accounts for a substantial share of CAR-T failures in B-cell malignancies and is emerging in multiple myeloma. Strategies include dual-target and tandem CARs, sequential products, and adaptor or universal CAR platforms whose specificity is set by a separately dosed molecule. A pragmatic programme would monitor antigen density after infusion and have the alternative product manufactured or an adaptor available before relapse.
Hypothesis
Pre-planned antigen switching, triggered by falling antigen density or early molecular relapse rather than by overt relapse, improves durable remission rates compared with reactive switching at relapse.
Rationale
Antigen loss is detectable before clinical relapse using flow cytometry and MRD assays; the delay in manufacturing a second product is usually what makes switching too late.
What would test it
Single-arm study of antigen-density and MRD-triggered pre-emptive switching in relapsed B-cell malignancy, with durable remission at two years compared with historical reactive management.
Maturity
early clinical
Who has to act
clinic
Cost to try
Medium ($1M to $50M)
Years to first evidence
5
Bottlenecks it attacks
- Acquired resistance to every therapy · Nearly every targeted therapy stops working within months to a few years as the tumour adapts.
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.